[{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio \/ Not Applicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio \/ Not Applicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio \/ Not Applicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio \/ Not Applicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AusperBio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by AusperBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.

Brand Name : AHB-137

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 10, 2024

Lead Product(s) : AHB-137

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.

Brand Name : AHB-137

Molecule Type : Large molecule

Upfront Cash : Not Applicable

February 14, 2024

Lead Product(s) : AHB-137

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : AHB-137 is an unconjugated antisense oligonucleotide, which is received FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment. he clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled s...

Brand Name : AHB-137

Molecule Type : Large molecule

Upfront Cash : Not Applicable

August 25, 2023

Lead Product(s) : AHB-137

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential treatment to be a backbone for the functional cure of Chronic Hepatitis B.

Brand Name : AHB-137

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 28, 2023

Lead Product(s) : AHB-137

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : AHB-137 is a potential best-in-class, highly potent, pan-genotypic antisense oligonucleotide (ASO) targeting all HBV RNA for the treatment of CHB patients. AHB-137 has shown best-in-class activity in reducing HBsAg across multiple preclinical models.

Brand Name : AHB-137

Molecule Type : Peptide

Upfront Cash : Not Applicable

March 09, 2023

Lead Product(s) : AHB-137

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank